When was LFB Biomanufacturing founded?

LFB Biomanufacturing was founded in 1994.

Where is LFB Biomanufacturing located?

LFB Biomanufacturing is headquartered in Ales, France.

How many employees does LFB Biomanufacturing have?

As of Aug 31, 2026, the latest employee count at LFB Biomanufacturing is 161.

Where does LFB Biomanufacturing rank among its competitors?

LFB Biomanufacturing ranks 19th amongst 44 active competitors, of which 4 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Kashiv BioSciences, which secured $72.3M in Dec, 2025.

Who are the top competitors of LFB Biomanufacturing?

LFB Biomanufacturing's top competitors include Bionova Scientific, Just Biotherapeutics and Avid Bioservices. Among them, Kashiv BioSciences secured the most recent funding round in December, 2025.

LFB Biomanufacturing - 2026 Company Profile & Competitors

LFB Biomanufacturing is an unfunded company based in Ales (France), founded in 1994. It operates as a Company offering CDMO services for biological production. LFB Biomanufacturing has not raised any funding yet. The company has 44 active competitors, including 4 funded and 14 that have exited. Its top competitors include companies like Bionova Scientific, Just Biotherapeutics and Avid Bioservices.

Company Details

LFB Biomanufacturing is a subsidiary of LFB Biotechnologies, offering CDMO services for biopharmaceuticals. Company's services range from the development of cell lines to the manufacturing of clinical and commercial batches of active substances from biological products using Single Use/Disposable Bioreactors Technology. Their development services include cell line development and banking (through their CHO-S platform, and EMABling® proprietary platform),process development, downstream processing and scale-up services. Their EMABling®(YB2/0-E cell line) proprietary platform can produce recombinant monoclonal antibodies with an enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) activity. Their manufacturing facilities are cGMP compliant and use single-use/disposable bioreactor technology. Their manufacturing capability ranges from non-GMP batches of 50L to 1000L. They are currently manufacturing 2 recombinant proteins which are developed by the LFB group and are currently undergoing advanced clinical trials.

Website: www.lfbbiomanufacturing.com/
Social
Email ID: *****@lfb.fr
Part Of

Key Metrics

Founded Year

1994

Location

Ales, France

Stage

Unfunded

Ranked

19^th among 44 active competitors

Employee Count

161 as on Aug 31, 2026

Similar Companies

Bionova Scientific & 51 more

View LFB Biomanufacturing's full profile

LFB Biomanufacturing has not raised any funding rounds yet.

LFB Biomanufacturing's employee count trend

LFB Biomanufacturing has 161 employees as of Aug 26. Here is LFB Biomanufacturing's employee count trend over the years:

Employee count trend for LFB Biomanufacturing

Uncover LFB Biomanufacturing's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LFB Biomanufacturing include Bionova Scientific, Just Biotherapeutics and Avid Bioservices. Here is the list of Top 10 competitors of LFB Biomanufacturing, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bionova Scientific 2013, Fremont (United States), Acquired	Contract Research and Development company developing mammalian cell culture biologics	$22M	CRG, Great Point Partners	54/100
2nd	Just Biotherapeutics 2014, Seattle (United States), Acquired	Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs	$124M	Lilly Asia Ventures, Temasek & 10 others	53/100
3rd	Avid Bioservices 2002, Orange (United States), Acquired	CDMO focused on drug substance development, analytical, and quality & regulatory compliance services	-	Ranger Investments, Ampersand Capital & 3 others	51/100
4th	JHL Biotech 2012, Hsinchu (Taiwan), Series D	CDMO solutions to companies developing and commercializing affordable biologics	$187M	Sanofi, Kleiner Perkins & 11 others	51/100
5th	Rentschler Biopharma 1927, Laupheim (Germany), Funding Raised	Full-service CDMO for biopharmaceuticals	-	-	50/100
6th	64x Bio 2017, San Francisco (United States), Series A	Developer of cell lines and production technologies for advanced therapies	$59.6M	First Round Capital, Fifty Years & 13 others	48/100
7th	Excellgene 2001, Monthey (Switzerland), Acquired	Provider of service covering value chain from DNA vector to purified protein	-	Kulczyk Investments, BioArk	48/100
8th	Kashiv BioSciences 2010, Piscataway (United States), Acquired	Developer of biosimilar medicines	-	GoldenTree	48/100
9th	ProBioGen AG 1994, Berlin (Germany), Acquired	Contract development and manufacturing organization focussed on therapeutic proteins/antibodies, viral vaccines and biosimilars	-	SudBG, SHS & 2 others	45/100
10th	AGC Biologics 2018, Bothell (United States), Unfunded	CDMO focused on development of mammalian and microbial-based therapeutic proteins	-	European Equity Partners	43/100
19th	LFB Biomanufacturing 1994, Ales (France), Unfunded	Company offering CDMO services for biological production	-	-	36/100